Compare GSK plc (GSK) vs YieldMax Nasdaq 100 0DTE Covered Call Strategy ETF (QDTY) Price & Performance

GSK trades at $52.64, up 2.7% on the day, with a bearish technical signal despite recent earnings beats. The company reported Q1 2026 EPS of $1.24, beating estimates of $1.16, and maintains strong profitability with a 17.78% net income margin. Positive clinical trial results for Jemperli in rectal cancer and FDA approval for Utebzi highlight pipeline strength, while a pending acquisition of Nuvalent, Inc. signals strategic expansion.

GSK offers value with a P/E of 13.71 and stable cash flows, but faces risks from clinical setbacks, as seen in the terminated Alector partnership. Analyst sentiment is mixed with 31% buy ratings, reflecting cautious optimism amid competitive and regulatory pressures. The stock's outlook hinges on execution of growth initiatives and pipeline developments.

QDTY trades at $40.02, down 2.77% on the day, with a bearish technical signal from moving averages and neutral oscillators. The stock exhibits consistent weekly dividend distributions, with recent payouts ranging from $0.22 to $0.32. Support and resistance levels are tightly clustered around $40–$42, indicating limited near-term price movement. Key financial ratios such as P/E, P/S, and ROE are unavailable, constraining fundamental valuation insights.

The outlook for QDTY is cautious due to the bearish technical trend and lack of transparent financial metrics. Investment appeal hinges on dividend consistency, but risks include opaque fundamentals and potential volatility. Investors require clearer earnings data and analyst coverage to assess long-term viability amid current market uncertainty.